The Impact of Vascular Disease Treatment on Platelet-Derived Microvesicles

被引:0
作者
Justyna Rosińska
Maria Łukasik
Wojciech Kozubski
机构
[1] Poznan University of Medical Sciences,Department of Neurology
来源
Cardiovascular Drugs and Therapy | 2017年 / 31卷
关键词
Platelet-derived microvesicles (pMV); Platelet-derived microparticles; Antiplatelet therapy; Statins; Cerebrovascular disease; Cardiovascular disease;
D O I
暂无
中图分类号
学科分类号
摘要
Platelet-derived microvesicles (pMVs) are small, heterogeneous vesicles released from platelet membranes as a result of activation. These microvesicles possess a wide range of properties, including prothrombotic, proatherogenic, proinflammatory, immunomodulatory, and even anticoagulant activity. The elevated release of these microvesicles has been observed in various metabolic, inflammatory, thrombotic, and vascular diseases, including ischemic heart disease, stroke, hypertension, diabetes, and connective tissue disease. Modulation of both pMV generation and the expression of their surface molecules may have beneficial clinical implications and could become a novel therapeutic target. However, mechanisms by which pharmacological agents can modify pMV formation are elusive. The purpose of this review is to discuss the effects of drugs routinely used in primary and secondary prevention of vascular disease on the release of pMV and expression of their surface procoagulant and proinflammatory molecules.
引用
收藏
页码:627 / 644
页数:17
相关论文
共 535 条
[61]  
Wallen H(1994)Amyloid-protein precursor-rich platelet microparticles in thrombotic disease Thromb Haemost 72 519-522
[62]  
Samad B(1991)Comparison of anticoagulant and procoagulant activities of stimulated platelets and platelet-derived microparticles Blood 77 2641-2648
[63]  
Nomura S(1997)Transcellular activation of platelets and endothelial cells by bioactive lipids in platelet microparticles J Clin Invest 99 2118-2127
[64]  
Shouzu A(2005)The platelet particle proteome J Proteome Res 4 1516-1521
[65]  
Omoto S(2007)Platelet microparticle membranes have 50- to 100-fold higher specific procoagulant activity than activated platelets Thromb Haemost 97 425-434
[66]  
Nishikawa M(2008)Function and role of microparticles in various clinical settings Thromb Res 123 8-23
[67]  
Fukuhara S(1991)Platelet derived microparticles express high affinity receptors for factor VIII J Biol Chem 266 17261-17268
[68]  
Nomura S(1992)Coagulation factor IXa binding to activated platelets and platelet derived microparticles: a flow cytometric study Thromb Haemost 68 74-78
[69]  
Shouzu A(2004)Hematopoietic cell-derived microparticle tissue factor contributes to fibrin formation during thrombus propagation Blood 104 3190-3197
[70]  
Omoto S(2004)Role of platelet microparticles in the production of thromboxane by rabbit pulmonary artery Hypertension 43 428-433